Double-blind, randomised, placebo-controlled, dose-finding phase IIb trial to evaluate the efficacy, safety, and tolerability of a 12-week-treatment with Naronapride in adult participants with at least moderate idiopathic or diabetic gastroparesis

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 10 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Naronapride (Primary)
Indications Diabetic gastroparesis; Gastroparesis
Focus Therapeutic Use
Acronyms MOVE-IT
Sponsors Dr Falk Pharma

Most Recent Events

04 Feb 2025 Planned End Date changed from 1 Apr 2025 to 1 Dec 2025.
04 Feb 2025 Planned primary completion date changed from 1 Jan 2025 to 1 Sep 2025.
13 Aug 2024 According to Renexxion media release, Jan Tack is Principal Investigator for the MOVE-IT study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight